| Current Price | $65.00 | Mkt Cap | $5.1B |
|---|---|---|---|
| Open | $65.37 | P/E Ratio | -9.67 |
| Prev. Close | $65.00 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $63.38 - $65.92 | Volume | 987,581 |
| 52-Wk Range | $38.94 - $86.95 | Avg. Daily Vol. | 1,288,187 |
| Current Price | $65.00 | Mkt Cap | $5.1B |
|---|---|---|---|
| Open | $65.37 | P/E Ratio | -9.67 |
| Prev. Close | $65.00 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $63.38 - $65.92 | Volume | 987,581 |
| 52-Wk Range | $38.94 - $86.95 | Avg. Daily Vol. | 1,288,187 |
The best Bull and Bear pitches based on recency and number of recommendations.
CRISPR gene editing is super exciting technology. Massive potential for the technology. Not much going on in the SR, waiting for the pipelines to mature.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about CRSP.
Recs
lemiwinx
(26.07)
Submitted: 7/18/2022 11:56:27 AM :
Start Price:
$79.20
NASDAQ:CRSP Score:
-30.55
CRISPR gene editing is super exciting technology. Massive potential for the technology. Not much going on in the SR, waiting for the pipelines to mature.
Recs
emtking
(47.99)
Submitted: 6/11/2022 11:44:05 AM :
Start Price:
$59.26
NASDAQ:CRSP Score:
-3.42
Short term pain for longer term gain. Great technology, but competition now in the space.
Recs
TMFAdriaCimino
(< 20)
Submitted: 1/14/2022 5:08:29 PM :
Start Price:
$66.51
NASDAQ:CRSP Score:
+4.26
A lot depends on Crispr's candidate for blood disorders. Crispr and partner Vertex aim to file for regulatory approval in late 2022. If this treatment gets the nod, I expect big gains for Crispr. That said, the stock is risky and if the treatment doesn't get approval, Crispr shares likely will suffer. So far, I'm optimistic considering clinical trial data.
Find the members with the highest scoring picks in CRSP.
CMFMLove (46.57) Score: +283.94
I'm generally bad at CAPS but I may have gotten this pick right. There's a long way to go, however, until we see commercial results from this technology.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| CMFMLove | 46.57 |
|
|
NS | $14.10 | +359.47% | +75.53% | +283.94 | 1 Comment | |
| Momentum21 | 50.50 | 10/24/2016 |
|
5Y | $14.05 | +361.10% | +99.39% | +261.71 | 0 Comment | |
| Playa14 | < 20 |
|
|
5Y | $15.13 | +328.19% | +75.45% | +252.74 | 0 Comment | |
| prankjt17530 | 25.30 | 2/13/2017 |
|
5Y | $15.21 | +325.94% | +84.53% | +241.41 | 0 Comment | |
| SHOPNVDA | < 20 | 6/26/2017 |
|
5Y | $16.84 | +284.71% | +75.58% | +209.12 | 0 Comment | |
| Capitalism | 71.89 | 5/15/2017 |
|
5Y | $17.05 | +279.97% | +78.35% | +201.62 | 1 Comment | |
| TMFFishBiz | < 20 | 11/13/2017 |
|
5Y | $17.91 | +261.73% | +65.80% | +195.93 | 0 Comment | |
| JF9383 | 36.64 | 12/6/2017 |
|
5Y | $18.44 | +251.33% | +62.91% | +188.42 | 0 Comment | |
| jeepdrew222 | 51.91 | 12/12/2017 |
|
5Y | $18.61 | +248.12% | +60.65% | +187.47 | 0 Comment | |
| portefeuille | 98.40 | 3/27/2017 |
|
5Y | $18.50 | +250.19% | +84.65% | +165.54 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
